Determination of Residual Anticoagulatory Effects of Fondaparinux
Information source: Johann Wolfgang Goethe University Hospitals
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Anticoagulant Prophylaxis/Therapy
Phase: N/A
Status: Recruiting
Sponsored by: Johann Wolfgang Goethe University Hospitals Official(s) and/or principal investigator(s): Marc Schindewolf, MD, Principal Investigator, Affiliation: J.W. Goethe University Hospital Frankfurt/M.
Overall contact: Marc Schindewolf, MD, Phone: +49 (0)69 6301, Ext: 5096, Email: marcschindewolf@yahoo.com
Summary
The purpose of this study is to determine residual anticoagulatory effects of a prophylactic
or therapeutic fondaparinux treatment i. e. prior to surgery/intervention, after pause of
therapy etc.
Clinical Details
Official title: Determination of Residual Anticoagulatory Effects of Prophylactic or Therapeutic Treatment With Fondaparinux
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: antiXa-levels (peak- and through-levels)
Secondary outcome: thromboembolic or bleeding episodes, HIT
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Fondaparinux therapy for at least 3 days
Exclusion Criteria:
- Age < 18 years
- Hemodialysis
Locations and Contacts
Marc Schindewolf, MD, Phone: +49 (0)69 6301, Ext: 5096, Email: marcschindewolf@yahoo.com
J.W. Goethe University Hospital Frankfurt/M., Frankfurt am Main, Hessen 60590, Germany; Recruiting Marc Schindewolf, MD, Phone: +49 (0)69-6301, Ext: 5096, Email: marcschindewolf@yahoo.com Edelgard Lindhoff-Last, MD, Phone: +49 (0)69-6301, Ext: 5096, Email: lindhoff-last@em.uni-frankfurt.de Marc Schindewolf, MD, Principal Investigator
Additional Information
Related publications: Paolucci F, Frasa H, Van Aarle F, Capdevla A, Clavies MC, van Dinther T, Donat F, Hendriks Y, van den Heuvel M, Nadal T, Lagrange F, Necciari J, Perez Y. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices. Clin Lab. 2003;49(9-10):451-60.
Starting date: April 2010
Last updated: April 12, 2010
|